Overall responses with coordinated pembrolizumab and high dose IL-2 (5-in-a-row schedule) for therapy of metastatic clear cell renal cancer: A single center, single arm trial.

Jonathan Alexander Chatzkel, Mayer Fishman, Steven P. Ludlow et al.|Journal of Clinical Oncology|2019

Cited by 8